Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating namilumab in active cardiac sarcoidosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Sarcoidosis
• Sarcoidosis

Drugs mentioned

• Namilumab (namilumab)

Snippet

Sponsor: Kinevant Sciences GmbH | Conditions: Sarcoidosis, Cardiac | Phase 2 | Status: TERMINATED | Results posted: 2025-04-17